C-KIT Expression in Orbital Cavernous Venous Hemangiomas
Orbital (slow flow) cavernous venous hemangiomas (OCVH) are the most common benign orbital tumors in adults. The c-KIT is a tyrosine kinase receptor, which is expressed on several types of cells, is thought to play a key role in tumor pathogenesis. The purpose of this study was to evaluate the prese...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/11/8/1199 |
| _version_ | 1827685747534069760 |
|---|---|
| author | Mizhir Atallah Natalia Edison Esther Levi Irit Elmalah Daniel Briscoe |
| author_facet | Mizhir Atallah Natalia Edison Esther Levi Irit Elmalah Daniel Briscoe |
| author_sort | Mizhir Atallah |
| collection | DOAJ |
| description | Orbital (slow flow) cavernous venous hemangiomas (OCVH) are the most common benign orbital tumors in adults. The c-KIT is a tyrosine kinase receptor, which is expressed on several types of cells, is thought to play a key role in tumor pathogenesis. The purpose of this study was to evaluate the presence of the receptor c-KIT in OCVH. Our retrospective study examined 16 orbital cavernous venous hemangiomas from 16 cases operated on between 2006–2016 at Emek Medical Center. The mean tumor size was 18.4 mm. Symptoms appeared between 6 months and 22 years before operation. All specimens were analyzed for the c-KIT receptor through immunohistochemistry. The c-KIT was expressed by the endothelium in all 16 preparates. Staining was strong in two cases, moderate in six, and weak in eight cases, with no statistically significant correlation between staining and tumor size (<i>p</i> = 0.69) or the symptom duration (<i>p</i> = 0.15). We conclude that c-KIT may play an important role in the pathogenesis of OCVH. This pilot study is significant in that tumor-targeted therapy such as Imatinib Mesylate and Sunitinib may have a role in treating surgically complicated cases located in the orbital apex. A large multicenter collaborative study is necessary to examine the role of c-KIT in OCVH. |
| first_indexed | 2024-03-10T08:58:51Z |
| format | Article |
| id | doaj.art-dac9251508c5416596bb096edabc6880 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-10T08:58:51Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-dac9251508c5416596bb096edabc68802023-11-22T06:56:14ZengMDPI AGBiomolecules2218-273X2021-08-01118119910.3390/biom11081199C-KIT Expression in Orbital Cavernous Venous HemangiomasMizhir Atallah0Natalia Edison1Esther Levi2Irit Elmalah3Daniel Briscoe4Ophthalmology Department, Emek Medical Center, Afula 18101, IsraelThe Tissue Diagnostics and Cancer Research Institute, Emek Medical Center, Afula 18101, IsraelLaboratory of Ophthalmic Research, Emek Medical Center, Afula 18101, IsraelThe Tissue Diagnostics and Cancer Research Institute, Emek Medical Center, Afula 18101, IsraelOphthalmology Department, Emek Medical Center, Afula 18101, IsraelOrbital (slow flow) cavernous venous hemangiomas (OCVH) are the most common benign orbital tumors in adults. The c-KIT is a tyrosine kinase receptor, which is expressed on several types of cells, is thought to play a key role in tumor pathogenesis. The purpose of this study was to evaluate the presence of the receptor c-KIT in OCVH. Our retrospective study examined 16 orbital cavernous venous hemangiomas from 16 cases operated on between 2006–2016 at Emek Medical Center. The mean tumor size was 18.4 mm. Symptoms appeared between 6 months and 22 years before operation. All specimens were analyzed for the c-KIT receptor through immunohistochemistry. The c-KIT was expressed by the endothelium in all 16 preparates. Staining was strong in two cases, moderate in six, and weak in eight cases, with no statistically significant correlation between staining and tumor size (<i>p</i> = 0.69) or the symptom duration (<i>p</i> = 0.15). We conclude that c-KIT may play an important role in the pathogenesis of OCVH. This pilot study is significant in that tumor-targeted therapy such as Imatinib Mesylate and Sunitinib may have a role in treating surgically complicated cases located in the orbital apex. A large multicenter collaborative study is necessary to examine the role of c-KIT in OCVH.https://www.mdpi.com/2218-273X/11/8/1199orbital cavernous hemangiomac-KITimmunohistochemistry |
| spellingShingle | Mizhir Atallah Natalia Edison Esther Levi Irit Elmalah Daniel Briscoe C-KIT Expression in Orbital Cavernous Venous Hemangiomas Biomolecules orbital cavernous hemangioma c-KIT immunohistochemistry |
| title | C-KIT Expression in Orbital Cavernous Venous Hemangiomas |
| title_full | C-KIT Expression in Orbital Cavernous Venous Hemangiomas |
| title_fullStr | C-KIT Expression in Orbital Cavernous Venous Hemangiomas |
| title_full_unstemmed | C-KIT Expression in Orbital Cavernous Venous Hemangiomas |
| title_short | C-KIT Expression in Orbital Cavernous Venous Hemangiomas |
| title_sort | c kit expression in orbital cavernous venous hemangiomas |
| topic | orbital cavernous hemangioma c-KIT immunohistochemistry |
| url | https://www.mdpi.com/2218-273X/11/8/1199 |
| work_keys_str_mv | AT mizhiratallah ckitexpressioninorbitalcavernousvenoushemangiomas AT nataliaedison ckitexpressioninorbitalcavernousvenoushemangiomas AT estherlevi ckitexpressioninorbitalcavernousvenoushemangiomas AT iritelmalah ckitexpressioninorbitalcavernousvenoushemangiomas AT danielbriscoe ckitexpressioninorbitalcavernousvenoushemangiomas |